Pfizer Inc. PFE on Tuesday reported better-than-expected first-quarter results and reaffirmed its 2026 financial guidance. This positive momentum comes alongside a broader market environment where S&P ...

Just four years into the rollout of Pfizer's pricey heart medication Vyndamax, the company is already playing patent defense against a potential copycat. In a new lawsuit, the drug giant and the ...

Pfizer has reached agreements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla, regarding lawsuits filed in the U.S. District Court for the District of Delaware. Vyndamax remains the market leader ...

Pfizer (NYSE: PFE) recently reached settlements with three generic drugmakers -- Hikma, Cipla, and Dexcel -- to extend the patent protection of Vyndamax, one of its best-selling drugs, through June ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Pfizer has reached legal settlements with three drug manufacturers related to alleged patent infringement for its Vyndamax drug. The biopharmaceutical company said Tuesday that it settled with Dexcel ...

Shares of BridgeBio Pharma (BBIO) slipped in the premarket on Tuesday after Raymond James downgraded the stock, citing the impact from the loss of exclusivity for Pfizer’s (PFE) heart drug Vyndamax, ...